Martin Shkreli Resigns as CEO of Turing Pharmaceuticals

After radically increasing the price a drug that can be a lifesaver for those with HIV, and later being arrested for securities fraud unrelated to his price-gouging, Turing Pharmaceuticals CEO Martin Shkreli has resigned.

Shkreli was hauled away in handcuffs Thursday in New York after being accused of a complicated shell game relating to another company he ran, involving secret payments and deceptive arrangements, all in an effort to pay off personal debts. Shkreli was previously accused of illegally using company stock for nonbusiness uses. The board of that company, Retrophin, ousted him and slapped him with a lawsuit. The 32-year-old executive formally quit Turing Friday, reports the Los Angeles Times. Ron Tilles, chairman of Turing's board of directors, will run the company on an interim basis.

The world became aware of Shkreli when he aquired the rights to Daraprim this summer and almost immediately raised the price by 5,000 percent, from $13.50 a pill to $750 a pill. Daraprim is essential in treating toxoplasmosis, a parasitic infection that can result in headaches, confusion, poor coordination, seizures, lung problems, and blurred vision. The infection can be fatal in people with compromised immune systems, including those with HIV or cancer.

Everyone from Hillary Clinton to Donald Trump blasted Shkreli's price increase, which he described as a smart business move. Democratic presidential candidate Bernie Sanders rejected Shkreli's donation of $2,700, giving it to an HIV clinic instead.

Trending stories

Joe Biden has tied the record for most LGBTQ+ judges confirmed in federal courts

Cowboys & Queens U.S. tour by Jane Hilton: A modern American dream

Katseye’s Lara Rajagopalan comes out, says she's 'half fruitcake'

From rock legends to Pride flags: Discover the vibrant LGBTQ+ scene in Asbury Park

Pride journey Walla Walla: An LGBTQ+ wine, food, and adventure getaway

Meet the cast of new lesbian dating show 'You Hauled'

France becomes world’s first country to enshrine abortion rights in constitution

Nathan Lane: Laugh through the 'dictatorship' with 'Mid-Century Modern'

Gerald Garth is keeping people of color happy and healthy through trying times

Nathan Lee Graham wants 'Mid-Century Modern's queer viewers to 'lean into the joy'

SFAF's Dr. Tyler TerMeer says he'll continue to fight for health care for all

Elon Musk uses burner accounts on X, doesn’t fact-check: report

Alan Cumming jumps for joy after major 'Avengers: Doomsday' casting news

Discover the power of Wellness in your life

All 6 rogue Mississippi cops got long prison sentences in 'Goon Squad' torture of 2 Black men

Season 4 of The Switch on resilience & radical self-love returns this spring

Discover why chic Costa Navarino is Europe's luxury getaway

Matt Bomer, as a 'Mid-Century Modern' ditz, can finally 'experience queer joy'

Where to stay in LGBTQ+ Ireland: Castles, domes and luxury retreats

Trump's orders prompt CDC to erase HIV resources

Olly Alexander's sexy new album 'Polari' is inspired by cruising & intimacy

Everything we know about Austin Wolf's arrest, court date & what happens next (updated)

How climate disasters hurt mental health in young people

In 'Mid-Century Modern,' the 'gay Avengers' assemble for needed comic relief

Kelly Marie Tran says all of her roles are queer — including her latest in 'Control Freak'

• 0
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8

With Shkreli gone, the Human Rights Campaign wants to know whether Turing will now lower the price of Daraprim.

"We hope that Martin Shkreli's departure will mark the end of Turing Pharmaceuticals' reckless price hikes on life-saving medications," Olivia Alair Dalton, HRC's Senior Vice President for Communications and Marketing, said in a statement. "Turing's interim CEO Ron Tilles should immediately roll back the company's unconscionable 5,000 percent price hike on Daraprim, a crucial treatment for many pregnant women and people living with HIV, and restore the drug to its original cost."